Advertisement


Mary K. Gospodarowicz, MD, on Challenges in Cancer Control

2015 European Cancer Congress

Advertisement

Mary K. Gospodarowicz, MD, of Princess Margaret Hospital, discusses the work of the Global Task Force on Radiotherapy for Cancer Control and its efforts to improve access to vital radiation treatment worldwide, especially in low- and middle-income countries.



Related Videos

Issues in Oncology

Federico Cappuzzo, MD, and Tony Mok, MD, on Managing EGFR Resistance in Lung Cancer

Federico Cappuzzo, MD, of Istituto Toscano Tumori-Ospedale Civile Livorno, and Tony Mok, MD, of The Chinese University of Hong Kong, discuss current strategies for treating patients with acquired resistance, and what the future holds for these patients.

Lung Cancer

Benjamin Besse, MD, PhD, and Tony Mok, MD, on Results of the BIRCH Clinical Trial

Benjamin Besse, MD, PhD, of the Institut Gustave Roussy, and Tony Mok, MD, of The Chinese University of Hong Kong, discuss this phase II trial of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1–selected NSCLC (Abstract 17LBA).

Global Cancer Care

Christoph Zielinski, MD: Highlights of 2015 European Cancer Congress

As Chair of the ECC Local Organizing Committee, Christoph Zielinski, MD, of the Medical University Vienna - General Hospital, shares his thoughts on the important goals and presentations of the 2015 Congress.

Kidney Cancer

Cora N. Sternberg, MD, on New Targets in Renal Cell Carcinoma

Cora N. Sternberg, MD, of San Camillo Forlanini Hospital, summarizes a teaching lecture on new targets in renal cell carcinoma, and discusses what to expect for the future of treating RCC.

Lung Cancer

Tony Mok, MD, and Alice Shaw, MD, PhD: Expert Perspectives on ALK Inhibition and Brigatinib

Tony Mok, MD, of The Chinese University of Hong Kong, and Alice Shaw, MD, PhD, of Massachusetts General Hospital, discuss the current status and future outlook of ALK inhibition, and an assessment of brigatinib CNS activity in patients with ALK-positive non-small cell lung cancer and intracranial metastases (Abstract 3061).

Advertisement

Advertisement




Advertisement